Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294832 | 0.87 | CYP4F2 (0.62) | CYP4F2CYP4A11PPARGPPARAABCB11 | |
| SCHEMBL9730220 | 0.85 | PPARG (0.57) | PPARGPPARACYP11B1CYP11B2USP30 | |
| SCHEMBL11338058 | 0.82 | KDM4E (0.58) | ABCB11KDM4EMEN1LMNAMAPT | |
| SCHEMBL23706586 | 0.82 | PPARG (0.55) | PPARGPPARACYP11B1CYP11B2USP30 | |
| SCHEMBL18115522 | 0.81 | PPARG (0.50) | PPARGPPARACYP11B1CYP11B2USP30 | |
| SCHEMBL823700 | 0.81 | CYP4F2 (0.50) | CYP4F2CYP4A11KDM4EMEN1LMNA | |
| SCHEMBL134715 | 0.81 | KMT2A (0.57) | ABCB11KDM4EMEN1LMNAMAPT | |
| SCHEMBL29517939 | 0.81 | LMNA (0.54) | PPARGPPARACYP11B1CYP11B2USP30 | |
| SCHEMBL22372583 | 0.81 | LMNA (0.54) | PPARGPPARACYP11B1CYP11B2USP30 | |
| SCHEMBL3666560 | 0.80 | SMN1; SMN2 (0.49) | PPARGPPARACYP11B1CYP11B2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| CN-106471635-B | The p doping cross-linking of organic hole transmission body | 西门子公司 | 2019-04-05 | — | — | CN | claimed |
| US-20180198069-A1 | P-Doping Cross-Linking Of Organic Hole Transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | claimed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117813293-A | Urea derivatives useful for the treatment of cancer | 蝎子疗法股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-1817282-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056752-A1 | PHENOXYACETIC ACID DERIVATIVES USEFUL FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | WO | disclosed |
| EP-0885885-B1 | PYRIDONE DERIVATIVES AND HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-6472348-B1 | Pyridone derivatives and herbicides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2002-10-29 | — | — | US | disclosed |
| US-6265349-B1 | Pyridone derivatives and herbicides | KUMIAI CHEMICAL INDUSTRY CO., LTD (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6048823-A | Pyridone derivatives and herbicides | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0885885-A1 | PYRIDONE DERIVATIVES AND HERBICIDES | KumaiI Chemical Industry Co., Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | CYP4F2 2605/4885CYP4A11 1724/4885PPARG 1852/4885 |
| US-20240158376-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | CYP4F2 3301/4885CYP4A11 1463/4885PPARG 515/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | CYP4F2 3301/4885CYP4A11 1463/4885PPARG 515/4885 |
| US-20090149448-A1 | Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases | PAOX, PCCA, PAH | CYP4F2 375/4885CYP4A11 247/4885PPARG 8/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | CYP4F2 3301/4885CYP4A11 1463/4885PPARG 515/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | CYP4F2 3301/4885CYP4A11 1463/4885PPARG 515/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | CYP4F2 3301/4885CYP4A11 1463/4885PPARG 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.